{"id":507047,"date":"2020-09-15T17:22:01","date_gmt":"2020-09-15T17:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=507047"},"modified":"2020-09-15T17:22:01","modified_gmt":"2020-09-15T17:22:01","slug":"bipolar-disorder-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-disorder-epidemiology-forecast-till-2030_507047.html","title":{"rendered":"Bipolar Disorder Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bipolar Disorder Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Bipolar Disorder Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s  &#8216;Bipolar Disorder Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Bipolar Disorder (Manic Depression) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">Bipolar Disorder, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed).<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-epidemiology-forecast\" target=\"_blank\"><strong>Bipolar Disorder&nbsp;Epidemiology Segmentation in 7 Major Market from 2017 to 2030<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Diagnosed Prevalence of Bipolar Depression<\/li>\n<li>Type-specific Diagnosed Prevalence of Bipolar Depression<\/li>\n<li>Severity-specific Diagnosed Prevalence of Bipolar Depression<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-epidemiology-forecast\" target=\"_blank\">Bipolar Disorder&nbsp;Epidemiology Insights<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total diagnosed prevalent population of Bipolar Depression in 7MM in 2017 was 1,857,545&nbsp;<\/li>\n<li>Type-specific diagnosed prevalent cases of Bipolar Depression in the US in 2017<br \/>Bipolar I cases &#8211; 291,134<br \/>Bipolar II cases &#8211; 449,581&nbsp;<\/li>\n<li>\n<p>Severity-specific diagnosed prevalence of Bipolar Depression in the US in 2017<br \/>28,666- Mild cases<br \/>158,735 &ndash; Moderate cases<br \/>553,092 &#8211; Severe cases<\/p>\n<\/li>\n<li>The diagnosed prevalence of Bipolar Depression in 2017<\/li>\n<ul>\n<li>United States &#8211; 740,715<\/li>\n<li>France &#8211; 278,145<\/li>\n<li>Spain &#8211; 89,599 &nbsp;<\/li>\n<li>Japan &#8211; 210,902<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-epidemiology-forecast\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-epidemiology-forecast\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1.&nbsp;Key Insights<\/span>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Bipolar Disorder (Manic Depression)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3.&nbsp;Bipolar Disorder (Manic Depression): Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1.&nbsp;Introduction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.2.&nbsp;Sign and Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.3.&nbsp;Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.4.&nbsp;Risk Factors<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.5.&nbsp;Diagnosis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4.&nbsp;Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5.&nbsp;Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.&nbsp;Epidemiology Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.2.&nbsp;Assumptions and Rationale: 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3.&nbsp;Epidemiology Scenario: 7MM<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.3.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in the 7MM (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4.&nbsp;United States Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.4.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in the United States (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.&nbsp;EU-5 Country-wise Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.5.1. Germany Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>5.5.1.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in Germany (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.5.2. France Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>5.5.2.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in France (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.5.3. Italy Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>5.5.3.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in Italy (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.5.4. Spain Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>5.5.4.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in Spain (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.5.5. United Kingdom Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>5.5.5.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.6. Japan Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>5.6.1.&nbsp;Bipolar Disorder (Manic Depression) Epidemiology Scenario in Japan (2017- 2030)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.1.&nbsp;Bipolar Disorder (Manic Depression) Treatment and Management<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.2.&nbsp;Bipolar Disorder (Manic Depression) Treatment Algorithm<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7.&nbsp;KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8.&nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9.&nbsp;&nbsp;Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.&nbsp;Bibliography<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.2.&nbsp;Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10.&nbsp;DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11.&nbsp;Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12.&nbsp;About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bipolar-disorder-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bipolar-disorder-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8216;Bipolar Disorder Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Bipolar Disorder (Manic Depression) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-disorder-epidemiology-forecast-till-2030_507047.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-507047","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/507047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=507047"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/507047\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=507047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=507047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=507047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}